1. Academic Validation
  2. EHE cell cultures: a platform for mechanistic and therapeutic investigation

EHE cell cultures: a platform for mechanistic and therapeutic investigation

  • bioRxiv. 2025 Mar 27:2025.03.24.644191. doi: 10.1101/2025.03.24.644191.
Nicholas Scalora Gillian DeWane Yuliia Drebot Ali A Khan Souradip Sinha Krishnendu Ghosh Denise Robinson Patricia Cogswell Andrew M Bellizzi Anthony N Snow Patrick Breheny Michael S Chimenti Munir R Tanas
Abstract

Epithelioid hemangioendothelioma (EHE) is a difficult to treat vascular sarcoma defined by TAZ- CAMTA1 or YAP-TFE3 fusion proteins. Human cell lines needed to further understand the pathogenesis of EHE have been lacking. Herein, we describe a method to generate EHE extended primary cell cultures. An integrated multi -omic and functional approach was used to characterize these cultures. The cell cultures, relatively homogenous by single cell RNA-Seq, demonstrated established characteristics of EHE including increased proliferation, anchorage independent growth, as well as the overall gene expression profile and secondary genetic alterations seen in EHE. Whole genome Sequencing (WGS) identified links to epigenetic modifying complexes, metabolic processes, and pointed to the importance of the extracellular matrix (ECM) in these tumors. Bulk RNA-Seq demonstrated upregulation of pathways including PI3K-Akt signaling, ECM/ECM receptor interaction, and the Hippo signaling pathway. Development of these extended primary cell cultures allowed for single-cell profiling which demonstrated different cell compartments within the cultures. Furthermore, the cultures served as a therapeutic platform to test the efficacy of TEAD inhibitors in vitro . Overall, the development of EHE primary cell cultures will aid in the mechanistic understanding of this sarcoma and serve as a model system to test new therapeutic approaches.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-153585
    99.39%, TEAD Inhibitor
    YAP
  • HY-134957
    99.89%, pan-TEAD Auto-Palmitoylation Inhibitor
    YAP